Q-omics provides the consensus-scored MIR4435-2HG profile across patient tissues and cancer cell-line models. MIR4435-2HG expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MIR4435-2HG is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, MIR4435-2HG RNA expression shows 18,336 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, KIRC, and ACC as cancer lineages where MIR4435-2HG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR4435-2HG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR4435-2HG survival associations across molecular data types. MIR4435-2HG RNA expression shows survival associations in the most cancer types (22), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR4435-2HG RNA expression–survival associations across cancer types. High MIR4435-2HG expression shows unfavorable associations in UVM, ACC, KIRP, HNSC, BRCA and MESO. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for MIR4435-2HG RNA expression.
This table summarizes MIR4435-2HG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR4435-2HG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR4435-2HG shows higher tumor expression in KIRC, HNSC, KIRP, COAD, BLCA and STAD. The KIRC box plot shows higher MIR4435-2HG RNA expression in tumor versus normal tissue (log2 FC = +1.697, t-test p < 0.001).
This table shows molecular features associated with MIR4435-2HG in patient tissues and cancer cell lines. In patient samples, MIR4435-2HG shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
